Targeting glucagon pathway may offer a new approach to treating diabetes
Maintaining the right level of sugar in the blood is the responsibility not only of insulin, which removes glucose, but also of a hormone called glucagon, which adds glucose.
For decades, treatments for type II diabetes have taken aim at insulin, but a new study suggests that a better approach may be to target glucagon's sweetening effect.
The findings were published today in the online edition of Cell Metabolism.
"What we've found is a way to reduce glucagon's influence on blood sugar without the side effects of global glucagon repression," said Ira Tabas, MD, PhD, Richard J. Stock Professor and Vice Chair of Research in the Department of Medicine and professor of Anatomy & Cell Biology (in Physiology and Cellular Biophysics), who led the study with Lale Ozcan, PhD, associate research scientist.
Though glucagon was discovered at the same time as insulin, research on it has languished compared with that of its cousin, and treatments have almost exclusively targeted the latter.
In the last decade, the success of incretins, a new class of drugs for type II diabetes, has sparked a renaissance in glucagon research. When they were first introduced, incretins were known to stimulate insulin secretion. But recent studies show that a significant part of their clinical success can be attributed to previously unsuspected inhibiting effects on glucagon secretion.
The experience with incretin has led to a renewed search for other drugs that act against glucagon, including compounds that block glucagon in the liver, where it acts to free glucose. Drugs that block the glucagon receptor in the liver have been tested, but glucagon has multiple roles, and recent early clinical trials show that it can raise cholesterol and lead to fat accumulation in the liver.
The new study shows how glucagon's effect on glucose could be disrupted without disturbing glucagon's other duties, raising prospects for a safer anti-glucagon diabetes treatment.
Drs. Tabas and Ozcan found that once glucagon binds to its receptor, glucose is fully released only after an enzyme called CaMKII is activated. When activated, CaMKII sends a protein called FoxO1 into the cell nucleus, where it turns on the genes needed for glucose secretion. A related pathway, working in parallel to this one, sends a FoxO1 helper protein into the cell nucleus, as reported in a paper on which Dr. Tabas is a co-author, published online on April 8 in Nature (embargoed until that time).
"Even when their disease is well controlled, most patients with type II diabetes have excess glucagon action, so blocking CaMKII could potentially be a new way to lower blood sugar and better treat the disease," said Dr. Tabas.
When the researchers blocked CaMKII in obese, diabetic mice, the animals' blood sugar went down, with no negative side effects. Instead, cholesterol declined, insulin sensitivity improved, and the liver became less fatty.
"Until now, it has been difficult to block glucagon's effect on blood sugar without interfering with glucagon's other functions," said Dr. Tabas, "but we think CaMKII is different."
Dr. Tabas is now working on the possibility of developing a CaMKII inhibitor to treat diabetes.
More information: Drs. Ozcan's and Tabas' paper is titled, "Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity."
Provided by
Columbia University Medical Center
-
Discovery of new signal pathway important to diabetes research
Jun 04, 2008 |
not rated yet |
0
-
Study pinpoints role of insulin on glucagon levels
Apr 07, 2009 |
not rated yet |
0
-
Researchers uncover potential 'cure' for type 1 diabetes
Jan 26, 2011 |
not rated yet |
0
-
Researchers discover protein that may represent new target for treating type 1 diabetes
Jan 04, 2012 |
not rated yet |
0
-
Research reveals hormone action that could lead to treatments for type 2 diabetes
Sep 30, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Please check what's in the Ulaby book regarding reflection.
3 hours ago
-
Question in reflection and transmission at oblique incidence.
7 hours ago
-
Is this plasma (picture in thread)
7 hours ago
-
Basic physics understanding. Could someone explain?
9 hours ago
-
Change in flux of a transformer
10 hours ago
-
Electric field between parallel plate capacitor
10 hours ago
- More from Physics Forums - Classical Physics
More news stories
Youth with type 2 diabetes at much higher risk for heart, kidney disease
The news about youth and diabetes keeps getting worse. The latest data from the national TODAY diabetes study shows that children who develop Type 2 diabetes are at high risk to develop heart, kidney and eye problems faster ...
Diabetes
13 hours ago |
not rated yet |
0
Type 2 diabetes progresses faster in kids, study finds
(HealthDay)—Type 2 diabetes is more aggressive in children than adults, with signs of serious complications seen just a few years after diagnosis, new research finds.
Diabetes
May 23, 2013 |
not rated yet |
0
Statin use is linked to increased risk of developing diabetes, warn researchers
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.
Diabetes
May 23, 2013 |
not rated yet |
0
Diabetes' genetic underpinnings can vary based on ethnic background, studies say
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
Diabetes
May 23, 2013 |
not rated yet |
0
|
Fish oil supplements may help fight against Type 2 diabetes
Widely-used fish oil supplements modestly increase amounts of a hormone that is associated with lower risk of diabetes and heart disease, according to a study accepted for publication in The Endocrine Society's Journal of ...
Diabetes
May 22, 2013 |
5 / 5 (2) |
1
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Help at hand for people with schizophrenia
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
Driving and hands-free talking lead to spike in errors, study shows
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.